Join
Live feed
·
PRReleasevia Quantisnow
Sarepta Therapeutics Inc. logo

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

ByQuantisnow·Wall Street's wire, on your screen.
SRPT· Sarepta Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SRPT (Sarepta Therapeutics Inc.) and more on Quantisnow.